Sipuleucel-T in Metastatic Castration-Resistant Prostate Concert Profile Report

被引：2
|
作者：
Plosker, Greg L. [1 ]
机构：
[1] Adis Int Ltd, Auckland 0754, New Zealand
来源：
BIODRUGS | 2011年 / 25卷 / 04期
关键词：
CANCER; IMMUNOTHERAPY; MITOXANTRONE; PREDNISONE; DOCETAXEL;
D O I：
10.2165/11207140-000000000-00000
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
[No abstract available]
引用
收藏
页码：255 / 256
页数：2
相关论文
共 50 条
  • [1] Sipuleucel-T In Metastatic Castration-Resistant Prostate Cancer
    Plosker, Greg L.
    DRUGS, 2011, 71 (01) : 101 - 108
  • [2] Targeted treatment of metastatic castration-resistant prostate cancer with sipuleucel-T immunotherapy
    Peter F. Mulders
    Maria De Santis
    Thomas Powles
    Karim Fizazi
    Cancer Immunology, Immunotherapy, 2015, 64 : 655 - 663
  • [3] SIPULEUCEL-T (PROVENGE®) FOR CASTRATION-RESISTANT PROSTATE CANCER
    Sartor, Oliver
    BJU INTERNATIONAL, 2012, 110 (2B) : E105 - E105
  • [4] Targeted treatment of metastatic castration-resistant prostate cancer with sipuleucel-T immunotherapy
    Mulders, Peter F.
    De Santis, Maria
    Powles, Thomas
    Fizazi, Karim
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2015, 64 (06) : 655 - 663
  • [5] Economic evaluation of sipuleucel-T immunotherapy in castration-resistant prostate cancer
    Holko, Przemyslaw
    Kawalec, Pawel
    EXPERT REVIEW OF ANTICANCER THERAPY, 2014, 14 (01) : 63 - 73
  • [6] Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer.
    Kantoff, Philip W.
    Higano, Celestia S.
    Shore, Neal D.
    Berger, E. Roy
    Small, Eric J.
    Penson, David F.
    Redfern, Charles H.
    Ferrari, Anna C.
    Dreicer, Robert
    Sims, Robert B.
    Xu, Yi
    Frohlich, Mark W.
    Schellhammer, Paul F.
    Ahmed, T.
    Amin, A.
    Arseneau, J.
    Barth, N.
    Bernstein, G.
    Bracken, B.
    Burch, P.
    Caggiano, V.
    Chin, J.
    Chodak, G.
    Chu, F.
    Corman, J.
    Curti, B.
    Dawson, N.
    Deeken, J. F.
    Dubernet, T.
    Fishman, M.
    Flanigan, R.
    Gailani, F.
    Garbo, L.
    Gardner, T.
    Gelmann, E.
    George, D.
    Godfrey, T.
    Gomella, L.
    Guerra, M.
    Hall, S.
    Hanson, J.
    Israeli, R.
    Jancis, E.
    Jewett, M. A. S.
    Kassabian, V.
    Katz, J.
    Klotz, L.
    Koeneman, K.
    Koh, H.
    Kratzke, R.
    NEW ENGLAND JOURNAL OF MEDICINE, 2010, 363 (05) : 411 - 422
  • [7] Interdisciplinary Critique of Sipuleucel-T as Immunotherapy in Castration-Resistant Prostate Cancer
    Huber, Marie L.
    Haynes, Laura
    Parker, Chris
    Iversen, Peter
    JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2012, 104 (04) : 273 - 279
  • [8] Cost-Effectiveness Analysis of Abiraterone and Sipuleucel-T in Asymptomatic Metastatic Castration-Resistant Prostate Cancer
    Gong, Cynthia L.
    Hay, Joel W.
    JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2014, 12 (10): : 1417 - 1425
  • [9] Complete Biochemical (Prostate-specific Antigen) Response to Sipuleucel-T With Enzalutamide in Castration-resistant Prostate Cancer: A Case Report With Implications for Future Research
    Graff, Julie N.
    Drake, Charles G.
    Beer, Tomasz M.
    UROLOGY, 2013, 81 (02) : 381 - 383
  • [10] A Transient Increase in Eosinophils Is Associated with Prolonged Survival in Men with Metastatic Castration-Resistant Prostate Cancer Who Receive Sipuleucel-T
    McNeel, Douglas G.
    Gardner, Thomas A.
    Higano, Celestia S.
    Kantoff, Philip W.
    Small, Eric J.
    Wener, Mark H.
    Sims, Robert B.
    DeVries, Todd
    Sheikh, Nadeem A.
    Dreicer, Robert
    CANCER IMMUNOLOGY RESEARCH, 2014, 2 (10) : 988 - 999
12345